Literature DB >> 28698974

Successful treatment of chronic refractory pouchitis with vedolizumab.

Fazia Mir1, Mohamad Hasan Yousef1, Edward Kenneth Partyka1, Veysel Tahan2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28698974     DOI： 10.1007/s00384-017-2854-0

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN： 0179-1958            Impact factor:   2.571


× No keyword cloud information.
  4 in total

Review 1.  Acute and chronic pouchitis--pathogenesis, diagnosis and treatment.

Authors:  Bo Shen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-04-17       Impact factor: 46.802

2.  Successful treatment of pouchitis with Vedolizumab, but not fecal microbiota transfer (FMT), after proctocolectomy in ulcerative colitis.

Authors:  Mona Schmid; Julia-Stefanie Frick; Nisar Malek; Martin Goetz
Journal:  Int J Colorectal Dis       Date:  2017-01-17       Impact factor: 2.571

3.  Efficacy of Vedolizumab in Patients with Antibiotic and Anti-tumor Necrosis Alpha Refractory Pouchitis.

Authors:  Jessica Philpott; Jean Ashburn; Bo Shen
Journal:  Inflamm Bowel Dis       Date:  2017-01       Impact factor: 5.325

4.  Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Authors:  Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245
  4 in total
  6 in total

1.  Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience.

Authors:  Bram Verstockt; Charlotte Claeys; Gert De Hertogh; Gert Van Assche; Albert Wolthuis; André D'Hoore; Séverine Vermeire; Marc Ferrante
Journal:  United European Gastroenterol J       Date:  2019-08-20       Impact factor: 4.623

2.  Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort.

Authors:  Martin Gregory; Kimberly N Weaver; Patrick Hoversten; Stephen Bradley Hicks; Devin Patel; Matthew A Ciorba; Alexandra M Gutierrez; Poonam Beniwal-Patel; Sowmya Palam; Gaurav Syal; Hans H Herfarth; George Christophi; Laura Raffals; Edward L Barnes; Parakkal Deepak
Journal:  Inflamm Bowel Dis       Date:  2019-08-20       Impact factor: 5.325

Review 3.  Outcomes and Management of the Ileal Pouch-Anal Anastomosis in the Elderly.

Authors:  James Q Zhou; Sean Michael Duenas; Tarik Kirat; Feza Remzi; Shannon Chang
Journal:  Curr Treat Options Gastroenterol       Date:  2018-09

4.  Vedolizumab for chronic antibiotic-refractory pouchitis.

Authors:  Amandeep Singh; Freeha Khan; Rocio Lopez; Bo Shen; Jessica Philpott
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-01-31

5.  α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis.

Authors:  Michaela Melde; Tanja M Müller; Ines Schneider; Carol-Immanuel Geppert; Laura Mühl; Laura Besendorf; Clarissa Allner; Emily Becker; Imke Atreya; Francesco Vitali; Raja Atreya; Markus F Neurath; Sebastian Zundler
Journal:  Therap Adv Gastroenterol       Date:  2021-11-24       Impact factor: 4.409

Review 6.  Medical treatment of pouchitis: a guide for the clinician.

Authors:  Wendy Rabbenou; Shannon Chang
Journal:  Therap Adv Gastroenterol       Date:  2021-06-27       Impact factor: 4.409
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.